Show simple item record

dc.contributor.authorHe, Jen_NZ
dc.contributor.authorBiswas, Ren_NZ
dc.contributor.authorBugde, Pen_NZ
dc.contributor.authorLi, Jen_NZ
dc.contributor.authorLiu, D-Xen_NZ
dc.contributor.authorLi, Yen_NZ
dc.date.accessioned2022-04-28T04:18:56Z
dc.date.available2022-04-28T04:18:56Z
dc.identifier.citationPharmaceutics, 14(5), 894. https://doi.org/10.3390/pharmaceutics14050894
dc.identifier.issn1999-4923en_NZ
dc.identifier.urihttp://hdl.handle.net/10292/15094
dc.description.abstractIn recent years, sequence-specific clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) systems have been widely used in genome editing of various cell types and organisms. The most developed and broadly used CRISPR-Cas system, CRISPR-Cas9, has benefited from the proof-of-principle studies for a better understanding of the function of genes associated with drug absorption and disposition. Genome-scale CRISPR-Cas9 knockout (KO) screen study also facilitates the identification of novel genes in which loss alters drug permeability across biological membranes and thus modulates the efficacy and safety of drugs. Compared with conventional heterogeneous expression models or other genome editing technologies, CRISPR-Cas9 gene manipulation techniques possess significant advantages, including ease of design, cost-effectiveness, greater on-target DNA cleavage activity and multiplexing capabilities, which makes it possible to study the interactions between membrane proteins and drugs more accurately and efficiently. However, many mechanistic questions and challenges regarding CRISPR-Cas9 gene editing are yet to be addressed, ranging from off-target effects to large-scale genetic alterations. In this review, an overview of the mechanisms of CRISPR-Cas9 in mammalian genome editing will be introduced, as well as the application of CRISPR-Cas9 in studying the barriers to drug delivery.en_NZ
dc.languageenen_NZ
dc.publisherMDPI AGen_NZ
dc.relation.urihttps://www.mdpi.com/1999-4923/14/5/894
dc.rights© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
dc.subjectCRISPR-Cas9; Blood-brain barrier; Intestinal epithelial barrier; Drug permeability
dc.titleApplication of CRISPR-Cas9 System to Study Biological Barriers to Drug Deliveryen_NZ
dc.typeJournal Article
dc.rights.accessrightsOpenAccessen_NZ
dc.identifier.doi10.3390/pharmaceutics14050894en_NZ
aut.relation.endpage894
aut.relation.issue5en_NZ
aut.relation.startpage894
aut.relation.volume14en_NZ
pubs.elements-id453694
aut.relation.journalPharmaceuticsen_NZ


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record